Charged Alpha logo
CHARGED ALPHA
Stock Analysis
Home Shows Games YouTube
Tools
Stock Screener Stocks Mutual Funds Funds ETF Screener ETFs Crypto Screener Crypto Options Scanner Options Bond Dashboard Rates REIT Screener REITs Forex Heatmap FX Commodities Futures Earnings Calendar Reports Precious Metals Metals Stock Charts Charts
Stock Library / GSK
GSK Unclassified Latest YouTube: Q2 2026 Published 2026-07-31

GSK

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

GSK (GSK): Profit Fell 75%, Core Earnings Rose 9% — Both Are True | Q2 2026

Published 2026-07-31

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q2 2026
2026-07-31
Podcast available
Yes
Current price
$51.69
-0.42 (-0.81%)
Trailing / Forward P/E
16.51x
Forward: 10.06x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
5.3%
Earnings: -69.5%
Margins
30.9% op
Gross: 73.5% · Net: 14.5%
Balance sheet
0.81x current
Debt / Equity: 106.5
52-week range / Beta
$36.75 - $61.70
Beta: 0.30
Analyst target
$58.08
Upside: 12.4%
Cash / shareholder return
3.36% FCF yield
Dividend yield: 1.31%

Company context

Industry: Drug Manufacturers - General
Country: United Kingdom
Employees: —
Price to book: 4.37x
Return on equity: 33.4%
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Price chart

Market context for GSK

Competitive view

GSK vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

GSK latest YouTube video thumbnail YouTube
GSK
GSK
YouTube Spotify Podbean
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
SS&C Technologies Holdings Inc. latest YouTube video thumbnail YouTube
SS&C Technologies Holdings Inc.
SSNC
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
GSK
$103.53B
GSK
SSNC
$18.56B
SS&C Technologies Holdings Inc.
DHR
$137.07B
Danaher Corporation
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
GSK
16.5x
GSK
SSNC
22.1x
SS&C Technologies Holdings Inc.
DHR
34.8x
Danaher Corporation
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
GSK
10.1x
GSK
SSNC
10.0x
SS&C Technologies Holdings Inc.
DHR
21.0x
Danaher Corporation
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
GSK
5.3%
GSK
SSNC
10.3%
SS&C Technologies Holdings Inc.
DHR
5.5%
Danaher Corporation
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
GSK
-69.5%
GSK
SSNC
34.7%
SS&C Technologies Holdings Inc.
DHR
59.7%
Danaher Corporation
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
GSK
30.9%
GSK
SSNC
24.6%
SS&C Technologies Holdings Inc.
DHR
19.8%
Danaher Corporation
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
GSK
73.5%
GSK
SSNC
48.1%
SS&C Technologies Holdings Inc.
DHR
58.8%
Danaher Corporation
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
GSK
14.5%
GSK
SSNC
13.2%
SS&C Technologies Holdings Inc.
DHR
15.9%
Danaher Corporation
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
GSK
33.4%
GSK
SSNC
12.6%
SS&C Technologies Holdings Inc.
DHR
7.6%
Danaher Corporation
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
GSK
3.4%
GSK
SSNC
7.0%
SS&C Technologies Holdings Inc.
DHR
3.2%
Danaher Corporation
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
GSK
106.50x
GSK
SSNC
115.90x
SS&C Technologies Holdings Inc.
DHR
52.97x
Danaher Corporation
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
GSK
0.81x
GSK
SSNC
1.06x
SS&C Technologies Holdings Inc.
DHR
1.65x
Danaher Corporation
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
GSK
0.30
GSK
SSNC
1.11
SS&C Technologies Holdings Inc.
DHR
0.82
Danaher Corporation
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
GSK
1.3%
GSK
SSNC
0.7%
SS&C Technologies Holdings Inc.
DHR
0.7%
Danaher Corporation
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
GSK
12.4%
GSK
SSNC
19.8%
SS&C Technologies Holdings Inc.
DHR
16.9%
Danaher Corporation

Related research

Non-quarter videos featuring GSK

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-31

GSK Profit Fell 75% — But Core Earnings Rose 9%. Both Are True. #GSK #stocks

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for GSK

Each row is one earnings episode with every verified platform link available.

Q2 2026
Episode live
2026-07-31
Published youtube podcast complete
GSK (GSK): Profit Fell 75%, Core Earnings Rose 9% — Both Are True | Q2 2026
Quarterly earnings-analysis entry for GSK. Use the links on the right to open the video or podcast episode.
YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music